Tarsus Pharmaceuticals Q1 2024 GAAP EPS $(1.01) Beats $(1.20) Estimate, Sales $27.614M Beat $17.460M Estimate
Tarsus Pharmaceuticals Q1 2024 GAAP EPS $(1.01) Beats $(1.20) Estimate, Sales $27.614M Beat $17.460M Estimate
Tarsus Pharmaceuticals 2024年第一季度GAAP每股收益美元（1.01美元）超過預期（1.20美元），銷售額2761.4萬美元超過預期的174.6億美元
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.20) by 15.83 percent. This is a 14.77 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $27.614 million which beat the analyst consensus estimate of $17.460 million by 58.16 percent. This is a 1.00K percent increase over sales of $2.500 million the same period last year.
塔蘇斯製藥公司（納斯達克股票代碼：TARS）公佈的季度虧損爲每股1.01美元，比分析師普遍預期的1.20美元（1.20美元）高出15.83％。這比去年同期每股虧損0.88美元（0.88美元）下降了14.77％。該公司公佈的季度銷售額爲2761.4萬美元，比分析師普遍預期的174.6億美元高出58.16％。這比去年同期的25億美元銷售額增長了1.00萬個百分點。